Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

NeuroMetrix, Inc.

https://www.neurometrix.com/

Latest From NeuroMetrix, Inc.

Asia Deal Watch: Astellas Begins 2023 Signing Rare Disease Tie-Ups With Selecta, Twist

Evopoint and Kaken also ring in the new year with multiple deals. Biocytogen licenses antibodies against a specified target derived from its RenMice platform technology to Hansoh Pharma.

Deal Watch Business Strategies

Digital Health Roundup: A Mixed Bag Of Exec Interviews; Femtech; Robotics; Digital OR; Wearables

In this month’s Digital Health roundup, Medtech Insight’s Marion Webb discusses her deep-dive article on menopause with leading experts in this rising industry and Barnaby Pickering highlights UK-based Proximie, which developed a web-based platform that allows surgeons and other clinical experts to collaborate virtually in the operating suite. The company recently raised $80m in a series C round.

Digital Health Artificial Intelligence

NeuroMetrix Rceives GSK 'Bridge' For Quell Wearable Pain-Relief Development

Recent modifications accelerated portion of milestones remaining in firms' agreement over the next 12 months, reduced GSK's aggregate amount payable and forwarded $2m to NeuroMetrix. Firms are co-funding future development of Quell technology and additional TENS products for chronic pain beginning in 2019.

Commercial Consumer

Market Intel: Peripheral Nerve Stim Players Edge Out Innovative Paths

While demand for spinal cord stimulation (SCS) devices used in pain management continues to expand at double-digit rates, a small but growing number of highly innovative companies that develop stimulators to specifically target peripheral nerve pain is creating excitement among pain doctors looking for better options to treat an intractable population that's seen little success with standard therapy. With millions of people worldwide suffering from low back pain, severe headaches and migraines, neck pain and other chronic pain, the demand for safe, effective, percutaneously-placed devices remains high. In this article, we'll highlight emerging companies working on PNS devices and provide insights from pain physicians on the pros and cons of these devices.

Neurology Commercial
See All

Company Information

  • Industry
  • Medical Devices
  • Medical Devices
    • Diagnostic Equipment & Supplies
    • Monitoring Equipment & Devices
  • In Vitro Diagnostics
    • Biosensors
UsernamePublicRestriction

Register